MRP : 48.70
AGIFIX® is indicated for the treatment of infections caused by susceptible bacteria:
• Upper respiratory tract infections, such as pharyngitis, sinusitis, otitis media, tonsillitis.
• Lower respiratory tract infections, such as acute bronchitis and acute exacerbation of chronic bronchitis.
• Uncomplicated urinary tract infections.
AGIFIX® is not advocated for those with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins.
Precautions & Warnings
AGIFIX® should be advocated with caution in presence of renal impairment or GI disease, particularly colitis. Prolonged use of AGIFIX® could result in overgrowth of non-susceptible organisms. If superinfections occur (usually involving Aerobacter, Pseudomonas or Candida spp), AGIFIX® should be discontinued and/or appropriate therapy instituted.
Periodic assessment of hematopoietic function is advisable during prolonged AGIFIX® therapy. AGIFIX® is not ideally meant for pregnant lady or lactating mother; however, it could be only if strictly necessary. Nursing discontinuation temporarily must be considered whilst taking AGIFIX®. Safety and efficacy of cefixime in children less than 6 months old have not been established.
AGIFIX® must be coadministered with carbamazepine, warfarin and other anticoagulants.
The most frequent adverse effect is gastrointestinal (GI) complaints, and diarrhea incidence is 16%. Other side effects include hypersensitivity reactions, liver / renal dysfunction, headaches, dizziness, seizures, hematopoietic changes, genital pruritus, vaginitis, candidiasis.
Elevated carbamazepine levels occur when cefixime AGIFIX® is coadministered. When given with warfarin / anticoagulants, the prothrombin time is elevated. Probenecid can decrease its clearance, whilst cholestyramine diminishes absorption of paracetamol when coadministered.
<50 kg: 8 mg/kg/day of AGIFIX® Suspension / AGIFIX® 50 / 100 DT either as single dose or in two divided doses. >50 kg:
AGIFIX® 50 Dry Syrup: 30 ml bottle with sterile water